Drug
Vemlidy
Vemlidy is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_4
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Not yet recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
not_yet_recruiting150%
active_not_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_4
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
NCT04496882
not_yet_recruitingphase_4
Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment
NCT06221657
Clinical Trials (2)
Showing 2 of 2 trials
NCT04496882Phase 4
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
NCT06221657Phase 4
Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2